Medical Care
Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Research Report 2025
- May 05, 25
- ID: 226584
- Pages: 77
- Figures: 76
- Views: 40
The global market for Chronic Graft-versus-host Disease (cGVHD) Treatment was valued at US$ 1666 million in the year 2024 and is projected to reach a revised size of US$ 2889 million by 2031, growing at a CAGR of 8.3% during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Chronic Graft-versus-host Disease (cGVHD) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Graft-versus-host Disease (cGVHD) Treatment.
The Chronic Graft-versus-host Disease (cGVHD) Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Chronic Graft-versus-host Disease (cGVHD) Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Graft-versus-host Disease (cGVHD) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck KGaA
Sanofi SA
Novartis AG
Bristol Myers Squibb
Pfizer
Roche Holding AG
Johnson & Johnson
Eli Lilly and Company
Abbott Laboratories
Takeda Pharmaceutical Company
Segment by Type
Corticosteroids
mTOR Inhibitors
Tyrosine Kinase Inhibitors
Monoclonal Antibodies
Others
Segment by Application
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chronic Graft-versus-host Disease (cGVHD) Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Chronic Graft-versus-host Disease (cGVHD) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Graft-versus-host Disease (cGVHD) Treatment.
The Chronic Graft-versus-host Disease (cGVHD) Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Chronic Graft-versus-host Disease (cGVHD) Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Graft-versus-host Disease (cGVHD) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck KGaA
Sanofi SA
Novartis AG
Bristol Myers Squibb
Pfizer
Roche Holding AG
Johnson & Johnson
Eli Lilly and Company
Abbott Laboratories
Takeda Pharmaceutical Company
Segment by Type
Corticosteroids
mTOR Inhibitors
Tyrosine Kinase Inhibitors
Monoclonal Antibodies
Others
Segment by Application
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chronic Graft-versus-host Disease (cGVHD) Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Corticosteroids
1.2.3 mTOR Inhibitors
1.2.4 Tyrosine Kinase Inhibitors
1.2.5 Monoclonal Antibodies
1.2.6 Others
1.3 Market by Application
1.3.1 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Perspective (2020-2031)
2.2 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Growth Trends by Region
2.2.1 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Chronic Graft-versus-host Disease (cGVHD) Treatment Historic Market Size by Region (2020-2025)
2.2.3 Chronic Graft-versus-host Disease (cGVHD) Treatment Forecasted Market Size by Region (2026-2031)
2.3 Chronic Graft-versus-host Disease (cGVHD) Treatment Market Dynamics
2.3.1 Chronic Graft-versus-host Disease (cGVHD) Treatment Industry Trends
2.3.2 Chronic Graft-versus-host Disease (cGVHD) Treatment Market Drivers
2.3.3 Chronic Graft-versus-host Disease (cGVHD) Treatment Market Challenges
2.3.4 Chronic Graft-versus-host Disease (cGVHD) Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chronic Graft-versus-host Disease (cGVHD) Treatment Players by Revenue
3.1.1 Global Top Chronic Graft-versus-host Disease (cGVHD) Treatment Players by Revenue (2020-2025)
3.1.2 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share by Players (2020-2025)
3.2 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue
3.4 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Concentration Ratio
3.4.1 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue in 2024
3.5 Global Key Players of Chronic Graft-versus-host Disease (cGVHD) Treatment Head office and Area Served
3.6 Global Key Players of Chronic Graft-versus-host Disease (cGVHD) Treatment, Product and Application
3.7 Global Key Players of Chronic Graft-versus-host Disease (cGVHD) Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Chronic Graft-versus-host Disease (cGVHD) Treatment Breakdown Data by Type
4.1 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Historic Market Size by Type (2020-2025)
4.2 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Forecasted Market Size by Type (2026-2031)
5 Chronic Graft-versus-host Disease (cGVHD) Treatment Breakdown Data by Application
5.1 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Historic Market Size by Application (2020-2025)
5.2 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size (2020-2031)
6.2 North America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2020-2025)
6.4 North America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size (2020-2031)
7.2 Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2020-2025)
7.4 Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size (2020-2031)
8.2 Asia-Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Region (2020-2025)
8.4 Asia-Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size (2020-2031)
9.2 Latin America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2020-2025)
9.4 Latin America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size (2020-2031)
10.2 Middle East & Africa Chronic Graft-versus-host Disease (cGVHD) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2020-2025)
10.4 Middle East & Africa Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Merck KGaA
11.1.1 Merck KGaA Company Details
11.1.2 Merck KGaA Business Overview
11.1.3 Merck KGaA Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction
11.1.4 Merck KGaA Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
11.1.5 Merck KGaA Recent Development
11.2 Sanofi SA
11.2.1 Sanofi SA Company Details
11.2.2 Sanofi SA Business Overview
11.2.3 Sanofi SA Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction
11.2.4 Sanofi SA Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
11.2.5 Sanofi SA Recent Development
11.3 Novartis AG
11.3.1 Novartis AG Company Details
11.3.2 Novartis AG Business Overview
11.3.3 Novartis AG Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction
11.3.4 Novartis AG Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
11.3.5 Novartis AG Recent Development
11.4 Bristol Myers Squibb
11.4.1 Bristol Myers Squibb Company Details
11.4.2 Bristol Myers Squibb Business Overview
11.4.3 Bristol Myers Squibb Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction
11.4.4 Bristol Myers Squibb Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
11.4.5 Bristol Myers Squibb Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction
11.5.4 Pfizer Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
11.5.5 Pfizer Recent Development
11.6 Roche Holding AG
11.6.1 Roche Holding AG Company Details
11.6.2 Roche Holding AG Business Overview
11.6.3 Roche Holding AG Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction
11.6.4 Roche Holding AG Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
11.6.5 Roche Holding AG Recent Development
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Details
11.7.2 Johnson & Johnson Business Overview
11.7.3 Johnson & Johnson Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction
11.7.4 Johnson & Johnson Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
11.7.5 Johnson & Johnson Recent Development
11.8 Eli Lilly and Company
11.8.1 Eli Lilly and Company Company Details
11.8.2 Eli Lilly and Company Business Overview
11.8.3 Eli Lilly and Company Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction
11.8.4 Eli Lilly and Company Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
11.8.5 Eli Lilly and Company Recent Development
11.9 Abbott Laboratories
11.9.1 Abbott Laboratories Company Details
11.9.2 Abbott Laboratories Business Overview
11.9.3 Abbott Laboratories Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction
11.9.4 Abbott Laboratories Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
11.9.5 Abbott Laboratories Recent Development
11.10 Takeda Pharmaceutical Company
11.10.1 Takeda Pharmaceutical Company Company Details
11.10.2 Takeda Pharmaceutical Company Business Overview
11.10.3 Takeda Pharmaceutical Company Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction
11.10.4 Takeda Pharmaceutical Company Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
11.10.5 Takeda Pharmaceutical Company Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Corticosteroids
1.2.3 mTOR Inhibitors
1.2.4 Tyrosine Kinase Inhibitors
1.2.5 Monoclonal Antibodies
1.2.6 Others
1.3 Market by Application
1.3.1 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Perspective (2020-2031)
2.2 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Growth Trends by Region
2.2.1 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Chronic Graft-versus-host Disease (cGVHD) Treatment Historic Market Size by Region (2020-2025)
2.2.3 Chronic Graft-versus-host Disease (cGVHD) Treatment Forecasted Market Size by Region (2026-2031)
2.3 Chronic Graft-versus-host Disease (cGVHD) Treatment Market Dynamics
2.3.1 Chronic Graft-versus-host Disease (cGVHD) Treatment Industry Trends
2.3.2 Chronic Graft-versus-host Disease (cGVHD) Treatment Market Drivers
2.3.3 Chronic Graft-versus-host Disease (cGVHD) Treatment Market Challenges
2.3.4 Chronic Graft-versus-host Disease (cGVHD) Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chronic Graft-versus-host Disease (cGVHD) Treatment Players by Revenue
3.1.1 Global Top Chronic Graft-versus-host Disease (cGVHD) Treatment Players by Revenue (2020-2025)
3.1.2 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share by Players (2020-2025)
3.2 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue
3.4 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Concentration Ratio
3.4.1 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue in 2024
3.5 Global Key Players of Chronic Graft-versus-host Disease (cGVHD) Treatment Head office and Area Served
3.6 Global Key Players of Chronic Graft-versus-host Disease (cGVHD) Treatment, Product and Application
3.7 Global Key Players of Chronic Graft-versus-host Disease (cGVHD) Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Chronic Graft-versus-host Disease (cGVHD) Treatment Breakdown Data by Type
4.1 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Historic Market Size by Type (2020-2025)
4.2 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Forecasted Market Size by Type (2026-2031)
5 Chronic Graft-versus-host Disease (cGVHD) Treatment Breakdown Data by Application
5.1 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Historic Market Size by Application (2020-2025)
5.2 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size (2020-2031)
6.2 North America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2020-2025)
6.4 North America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size (2020-2031)
7.2 Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2020-2025)
7.4 Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size (2020-2031)
8.2 Asia-Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Region (2020-2025)
8.4 Asia-Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size (2020-2031)
9.2 Latin America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2020-2025)
9.4 Latin America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size (2020-2031)
10.2 Middle East & Africa Chronic Graft-versus-host Disease (cGVHD) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2020-2025)
10.4 Middle East & Africa Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Merck KGaA
11.1.1 Merck KGaA Company Details
11.1.2 Merck KGaA Business Overview
11.1.3 Merck KGaA Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction
11.1.4 Merck KGaA Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
11.1.5 Merck KGaA Recent Development
11.2 Sanofi SA
11.2.1 Sanofi SA Company Details
11.2.2 Sanofi SA Business Overview
11.2.3 Sanofi SA Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction
11.2.4 Sanofi SA Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
11.2.5 Sanofi SA Recent Development
11.3 Novartis AG
11.3.1 Novartis AG Company Details
11.3.2 Novartis AG Business Overview
11.3.3 Novartis AG Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction
11.3.4 Novartis AG Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
11.3.5 Novartis AG Recent Development
11.4 Bristol Myers Squibb
11.4.1 Bristol Myers Squibb Company Details
11.4.2 Bristol Myers Squibb Business Overview
11.4.3 Bristol Myers Squibb Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction
11.4.4 Bristol Myers Squibb Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
11.4.5 Bristol Myers Squibb Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction
11.5.4 Pfizer Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
11.5.5 Pfizer Recent Development
11.6 Roche Holding AG
11.6.1 Roche Holding AG Company Details
11.6.2 Roche Holding AG Business Overview
11.6.3 Roche Holding AG Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction
11.6.4 Roche Holding AG Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
11.6.5 Roche Holding AG Recent Development
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Details
11.7.2 Johnson & Johnson Business Overview
11.7.3 Johnson & Johnson Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction
11.7.4 Johnson & Johnson Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
11.7.5 Johnson & Johnson Recent Development
11.8 Eli Lilly and Company
11.8.1 Eli Lilly and Company Company Details
11.8.2 Eli Lilly and Company Business Overview
11.8.3 Eli Lilly and Company Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction
11.8.4 Eli Lilly and Company Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
11.8.5 Eli Lilly and Company Recent Development
11.9 Abbott Laboratories
11.9.1 Abbott Laboratories Company Details
11.9.2 Abbott Laboratories Business Overview
11.9.3 Abbott Laboratories Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction
11.9.4 Abbott Laboratories Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
11.9.5 Abbott Laboratories Recent Development
11.10 Takeda Pharmaceutical Company
11.10.1 Takeda Pharmaceutical Company Company Details
11.10.2 Takeda Pharmaceutical Company Business Overview
11.10.3 Takeda Pharmaceutical Company Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction
11.10.4 Takeda Pharmaceutical Company Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
11.10.5 Takeda Pharmaceutical Company Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Corticosteroids
Table 3. Key Players of mTOR Inhibitors
Table 4. Key Players of Tyrosine Kinase Inhibitors
Table 5. Key Players of Monoclonal Antibodies
Table 6. Key Players of Others
Table 7. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 10. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Region (2020-2025)
Table 11. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 12. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Region (2026-2031)
Table 13. Chronic Graft-versus-host Disease (cGVHD) Treatment Market Trends
Table 14. Chronic Graft-versus-host Disease (cGVHD) Treatment Market Drivers
Table 15. Chronic Graft-versus-host Disease (cGVHD) Treatment Market Challenges
Table 16. Chronic Graft-versus-host Disease (cGVHD) Treatment Market Restraints
Table 17. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue by Players (2020-2025) & (US$ Million)
Table 18. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Players (2020-2025)
Table 19. Global Top Chronic Graft-versus-host Disease (cGVHD) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment as of 2024)
Table 20. Ranking of Global Top Chronic Graft-versus-host Disease (cGVHD) Treatment Companies by Revenue (US$ Million) in 2024
Table 21. Global 5 Largest Players Market Share by Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue (CR5 and HHI) & (2020-2025)
Table 22. Global Key Players of Chronic Graft-versus-host Disease (cGVHD) Treatment, Headquarters and Area Served
Table 23. Global Key Players of Chronic Graft-versus-host Disease (cGVHD) Treatment, Product and Application
Table 24. Global Key Players of Chronic Graft-versus-host Disease (cGVHD) Treatment, Date of Enter into This Industry
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Type (2020-2025) & (US$ Million)
Table 27. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share by Type (2020-2025)
Table 28. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 29. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share by Type (2026-2031)
Table 30. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Application (2020-2025) & (US$ Million)
Table 31. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share by Application (2020-2025)
Table 32. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 33. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share by Application (2026-2031)
Table 34. North America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. North America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 36. North America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 37. Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 38. Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 39. Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 40. Asia-Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 41. Asia-Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 42. Asia-Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Region (2026-2031) & (US$ Million)
Table 43. Latin America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Latin America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 45. Latin America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 46. Middle East & Africa Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 47. Middle East & Africa Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 48. Middle East & Africa Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 49. Merck KGaA Company Details
Table 50. Merck KGaA Business Overview
Table 51. Merck KGaA Chronic Graft-versus-host Disease (cGVHD) Treatment Product
Table 52. Merck KGaA Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025) & (US$ Million)
Table 53. Merck KGaA Recent Development
Table 54. Sanofi SA Company Details
Table 55. Sanofi SA Business Overview
Table 56. Sanofi SA Chronic Graft-versus-host Disease (cGVHD) Treatment Product
Table 57. Sanofi SA Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025) & (US$ Million)
Table 58. Sanofi SA Recent Development
Table 59. Novartis AG Company Details
Table 60. Novartis AG Business Overview
Table 61. Novartis AG Chronic Graft-versus-host Disease (cGVHD) Treatment Product
Table 62. Novartis AG Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025) & (US$ Million)
Table 63. Novartis AG Recent Development
Table 64. Bristol Myers Squibb Company Details
Table 65. Bristol Myers Squibb Business Overview
Table 66. Bristol Myers Squibb Chronic Graft-versus-host Disease (cGVHD) Treatment Product
Table 67. Bristol Myers Squibb Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025) & (US$ Million)
Table 68. Bristol Myers Squibb Recent Development
Table 69. Pfizer Company Details
Table 70. Pfizer Business Overview
Table 71. Pfizer Chronic Graft-versus-host Disease (cGVHD) Treatment Product
Table 72. Pfizer Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025) & (US$ Million)
Table 73. Pfizer Recent Development
Table 74. Roche Holding AG Company Details
Table 75. Roche Holding AG Business Overview
Table 76. Roche Holding AG Chronic Graft-versus-host Disease (cGVHD) Treatment Product
Table 77. Roche Holding AG Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025) & (US$ Million)
Table 78. Roche Holding AG Recent Development
Table 79. Johnson & Johnson Company Details
Table 80. Johnson & Johnson Business Overview
Table 81. Johnson & Johnson Chronic Graft-versus-host Disease (cGVHD) Treatment Product
Table 82. Johnson & Johnson Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025) & (US$ Million)
Table 83. Johnson & Johnson Recent Development
Table 84. Eli Lilly and Company Company Details
Table 85. Eli Lilly and Company Business Overview
Table 86. Eli Lilly and Company Chronic Graft-versus-host Disease (cGVHD) Treatment Product
Table 87. Eli Lilly and Company Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025) & (US$ Million)
Table 88. Eli Lilly and Company Recent Development
Table 89. Abbott Laboratories Company Details
Table 90. Abbott Laboratories Business Overview
Table 91. Abbott Laboratories Chronic Graft-versus-host Disease (cGVHD) Treatment Product
Table 92. Abbott Laboratories Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025) & (US$ Million)
Table 93. Abbott Laboratories Recent Development
Table 94. Takeda Pharmaceutical Company Company Details
Table 95. Takeda Pharmaceutical Company Business Overview
Table 96. Takeda Pharmaceutical Company Chronic Graft-versus-host Disease (cGVHD) Treatment Product
Table 97. Takeda Pharmaceutical Company Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025) & (US$ Million)
Table 98. Takeda Pharmaceutical Company Recent Development
Table 99. Research Programs/Design for This Report
Table 100. Key Data Information from Secondary Sources
Table 101. Key Data Information from Primary Sources
Table 102. Authors List of This Report
List of Figures
Figure 1. Chronic Graft-versus-host Disease (cGVHD) Treatment Picture
Figure 2. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Type: 2024 VS 2031
Figure 4. Corticosteroids Features
Figure 5. mTOR Inhibitors Features
Figure 6. Tyrosine Kinase Inhibitors Features
Figure 7. Monoclonal Antibodies Features
Figure 8. Others Features
Figure 9. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Application (2020-2031) & (US$ Million)
Figure 10. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Application: 2024 VS 2031
Figure 11. Hospitals Pharmacies Case Studies
Figure 12. Retail Pharmacies Case Studies
Figure 13. Online Pharmacies Case Studies
Figure 14. Chronic Graft-versus-host Disease (cGVHD) Treatment Report Years Considered
Figure 15. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 16. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Region: 2024 VS 2031
Figure 18. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Players in 2024
Figure 19. Global Top Chronic Graft-versus-host Disease (cGVHD) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment as of 2024)
Figure 20. The Top 10 and 5 Players Market Share by Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue in 2024
Figure 21. North America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. North America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Country (2020-2031)
Figure 23. United States Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Canada Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Country (2020-2031)
Figure 27. Germany Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. France Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. U.K. Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Italy Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Russia Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Nordic Countries Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Region (2020-2031)
Figure 35. China Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Japan Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. South Korea Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Southeast Asia Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. India Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Australia Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Country (2020-2031)
Figure 43. Mexico Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Brazil Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Country (2020-2031)
Figure 47. Turkey Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Saudi Arabia Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. UAE Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Merck KGaA Revenue Growth Rate in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
Figure 51. Sanofi SA Revenue Growth Rate in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
Figure 52. Novartis AG Revenue Growth Rate in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
Figure 53. Bristol Myers Squibb Revenue Growth Rate in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
Figure 54. Pfizer Revenue Growth Rate in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
Figure 55. Roche Holding AG Revenue Growth Rate in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
Figure 56. Johnson & Johnson Revenue Growth Rate in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
Figure 57. Eli Lilly and Company Revenue Growth Rate in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
Figure 58. Abbott Laboratories Revenue Growth Rate in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
Figure 59. Takeda Pharmaceutical Company Revenue Growth Rate in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Table 1. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Corticosteroids
Table 3. Key Players of mTOR Inhibitors
Table 4. Key Players of Tyrosine Kinase Inhibitors
Table 5. Key Players of Monoclonal Antibodies
Table 6. Key Players of Others
Table 7. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 10. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Region (2020-2025)
Table 11. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 12. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Region (2026-2031)
Table 13. Chronic Graft-versus-host Disease (cGVHD) Treatment Market Trends
Table 14. Chronic Graft-versus-host Disease (cGVHD) Treatment Market Drivers
Table 15. Chronic Graft-versus-host Disease (cGVHD) Treatment Market Challenges
Table 16. Chronic Graft-versus-host Disease (cGVHD) Treatment Market Restraints
Table 17. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue by Players (2020-2025) & (US$ Million)
Table 18. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Players (2020-2025)
Table 19. Global Top Chronic Graft-versus-host Disease (cGVHD) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment as of 2024)
Table 20. Ranking of Global Top Chronic Graft-versus-host Disease (cGVHD) Treatment Companies by Revenue (US$ Million) in 2024
Table 21. Global 5 Largest Players Market Share by Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue (CR5 and HHI) & (2020-2025)
Table 22. Global Key Players of Chronic Graft-versus-host Disease (cGVHD) Treatment, Headquarters and Area Served
Table 23. Global Key Players of Chronic Graft-versus-host Disease (cGVHD) Treatment, Product and Application
Table 24. Global Key Players of Chronic Graft-versus-host Disease (cGVHD) Treatment, Date of Enter into This Industry
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Type (2020-2025) & (US$ Million)
Table 27. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share by Type (2020-2025)
Table 28. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 29. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share by Type (2026-2031)
Table 30. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Application (2020-2025) & (US$ Million)
Table 31. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share by Application (2020-2025)
Table 32. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 33. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share by Application (2026-2031)
Table 34. North America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. North America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 36. North America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 37. Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 38. Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 39. Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 40. Asia-Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 41. Asia-Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 42. Asia-Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Region (2026-2031) & (US$ Million)
Table 43. Latin America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Latin America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 45. Latin America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 46. Middle East & Africa Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 47. Middle East & Africa Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 48. Middle East & Africa Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 49. Merck KGaA Company Details
Table 50. Merck KGaA Business Overview
Table 51. Merck KGaA Chronic Graft-versus-host Disease (cGVHD) Treatment Product
Table 52. Merck KGaA Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025) & (US$ Million)
Table 53. Merck KGaA Recent Development
Table 54. Sanofi SA Company Details
Table 55. Sanofi SA Business Overview
Table 56. Sanofi SA Chronic Graft-versus-host Disease (cGVHD) Treatment Product
Table 57. Sanofi SA Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025) & (US$ Million)
Table 58. Sanofi SA Recent Development
Table 59. Novartis AG Company Details
Table 60. Novartis AG Business Overview
Table 61. Novartis AG Chronic Graft-versus-host Disease (cGVHD) Treatment Product
Table 62. Novartis AG Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025) & (US$ Million)
Table 63. Novartis AG Recent Development
Table 64. Bristol Myers Squibb Company Details
Table 65. Bristol Myers Squibb Business Overview
Table 66. Bristol Myers Squibb Chronic Graft-versus-host Disease (cGVHD) Treatment Product
Table 67. Bristol Myers Squibb Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025) & (US$ Million)
Table 68. Bristol Myers Squibb Recent Development
Table 69. Pfizer Company Details
Table 70. Pfizer Business Overview
Table 71. Pfizer Chronic Graft-versus-host Disease (cGVHD) Treatment Product
Table 72. Pfizer Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025) & (US$ Million)
Table 73. Pfizer Recent Development
Table 74. Roche Holding AG Company Details
Table 75. Roche Holding AG Business Overview
Table 76. Roche Holding AG Chronic Graft-versus-host Disease (cGVHD) Treatment Product
Table 77. Roche Holding AG Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025) & (US$ Million)
Table 78. Roche Holding AG Recent Development
Table 79. Johnson & Johnson Company Details
Table 80. Johnson & Johnson Business Overview
Table 81. Johnson & Johnson Chronic Graft-versus-host Disease (cGVHD) Treatment Product
Table 82. Johnson & Johnson Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025) & (US$ Million)
Table 83. Johnson & Johnson Recent Development
Table 84. Eli Lilly and Company Company Details
Table 85. Eli Lilly and Company Business Overview
Table 86. Eli Lilly and Company Chronic Graft-versus-host Disease (cGVHD) Treatment Product
Table 87. Eli Lilly and Company Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025) & (US$ Million)
Table 88. Eli Lilly and Company Recent Development
Table 89. Abbott Laboratories Company Details
Table 90. Abbott Laboratories Business Overview
Table 91. Abbott Laboratories Chronic Graft-versus-host Disease (cGVHD) Treatment Product
Table 92. Abbott Laboratories Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025) & (US$ Million)
Table 93. Abbott Laboratories Recent Development
Table 94. Takeda Pharmaceutical Company Company Details
Table 95. Takeda Pharmaceutical Company Business Overview
Table 96. Takeda Pharmaceutical Company Chronic Graft-versus-host Disease (cGVHD) Treatment Product
Table 97. Takeda Pharmaceutical Company Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025) & (US$ Million)
Table 98. Takeda Pharmaceutical Company Recent Development
Table 99. Research Programs/Design for This Report
Table 100. Key Data Information from Secondary Sources
Table 101. Key Data Information from Primary Sources
Table 102. Authors List of This Report
List of Figures
Figure 1. Chronic Graft-versus-host Disease (cGVHD) Treatment Picture
Figure 2. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Type: 2024 VS 2031
Figure 4. Corticosteroids Features
Figure 5. mTOR Inhibitors Features
Figure 6. Tyrosine Kinase Inhibitors Features
Figure 7. Monoclonal Antibodies Features
Figure 8. Others Features
Figure 9. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Application (2020-2031) & (US$ Million)
Figure 10. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Application: 2024 VS 2031
Figure 11. Hospitals Pharmacies Case Studies
Figure 12. Retail Pharmacies Case Studies
Figure 13. Online Pharmacies Case Studies
Figure 14. Chronic Graft-versus-host Disease (cGVHD) Treatment Report Years Considered
Figure 15. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 16. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Region: 2024 VS 2031
Figure 18. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Players in 2024
Figure 19. Global Top Chronic Graft-versus-host Disease (cGVHD) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment as of 2024)
Figure 20. The Top 10 and 5 Players Market Share by Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue in 2024
Figure 21. North America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. North America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Country (2020-2031)
Figure 23. United States Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Canada Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Country (2020-2031)
Figure 27. Germany Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. France Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. U.K. Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Italy Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Russia Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Nordic Countries Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Region (2020-2031)
Figure 35. China Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Japan Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. South Korea Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Southeast Asia Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. India Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Australia Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Country (2020-2031)
Figure 43. Mexico Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Brazil Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Country (2020-2031)
Figure 47. Turkey Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Saudi Arabia Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. UAE Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Merck KGaA Revenue Growth Rate in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
Figure 51. Sanofi SA Revenue Growth Rate in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
Figure 52. Novartis AG Revenue Growth Rate in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
Figure 53. Bristol Myers Squibb Revenue Growth Rate in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
Figure 54. Pfizer Revenue Growth Rate in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
Figure 55. Roche Holding AG Revenue Growth Rate in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
Figure 56. Johnson & Johnson Revenue Growth Rate in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
Figure 57. Eli Lilly and Company Revenue Growth Rate in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
Figure 58. Abbott Laboratories Revenue Growth Rate in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
Figure 59. Takeda Pharmaceutical Company Revenue Growth Rate in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Potassium Bromide Windows Market Research Report 2025
Dec 14, 25
Global Bio-based 1,10-Decanediol Diacrylate Market Research Report 2025
Dec 14, 25
Global Bio-based 1,5-Pentanediol Diacrylate(PDDA) Market Research Report 2025
Dec 14, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232